Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad Genetics has announced results of the Act-Earli-AD trial, an 18-month Phase III study of Flurizan in patients with mild Alzheimer's disease.
Subscribe to our email newsletter
The study did not achieve statistical significance on either of its primary endpoints – cognition and activities of daily living.
Peter Meldrum, president and CEO of Myriad Genetics, said: “We are disappointed that Flurizan failed to achieve significance in this study, and we will now discontinue development of this compound. The discontinuation of Flurizan will reduce our pharmaceutical development spend substantially and should enable Myriad to achieve profitability next year, ending June 30, 2009.”